CN1409631A - 新制剂 - Google Patents
新制剂 Download PDFInfo
- Publication number
- CN1409631A CN1409631A CN00816883A CN00816883A CN1409631A CN 1409631 A CN1409631 A CN 1409631A CN 00816883 A CN00816883 A CN 00816883A CN 00816883 A CN00816883 A CN 00816883A CN 1409631 A CN1409631 A CN 1409631A
- Authority
- CN
- China
- Prior art keywords
- solvent
- buddhist nun
- preparation
- wonderful woods
- free alkali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract description 7
- 238000009472 formulation Methods 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000002347 injection Methods 0.000 claims abstract description 13
- 239000007924 injection Substances 0.000 claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 238000011065 in-situ storage Methods 0.000 claims abstract description 7
- 244000144972 livestock Species 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims description 35
- 239000003513 alkali Substances 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 12
- 239000011877 solvent mixture Substances 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229960002903 benzyl benzoate Drugs 0.000 claims description 6
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 150000001991 dicarboxylic acids Chemical group 0.000 claims description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- LLYYNOVSVPBRGV-MVNKZKPCSA-N valnemulin Chemical compound CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 LLYYNOVSVPBRGV-MVNKZKPCSA-N 0.000 abstract description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 229950008166 valnemulin Drugs 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 241001430197 Mollicutes Species 0.000 description 9
- 229960004756 ethanol Drugs 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000032923 Lobar pneumonia Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000078104 Acholeplasma granularum Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001148567 Lawsonia intracellularis Species 0.000 description 1
- 241000202956 Mycoplasma arthritidis Species 0.000 description 1
- 241000202955 Mycoplasma bovigenitalium Species 0.000 description 1
- 241001148552 Mycoplasma canis Species 0.000 description 1
- 241000202896 Mycoplasma neurolyticum Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241001501970 Prionailurus bengalensis Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- -1 alkaline earth metal carbonate Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明描述了喔尼妙林的改善的盖伦给药形式的制备，该给药形式的特点在于其耐受性良好并且存放稳定。所述的新的给药形式是非水或油性的注射制剂，可以通过就地制备相对不稳定的活性成分的游离碱并随后使其稳定制得。本发明的另一方面涉及所述注射制剂在治疗生产性牲畜或家畜传染病的方法中的用途。
Description
本发明涉及喔尼妙林(valnemulin)的改善的盖伦给药形式的制备方法，该给药形式的特点在于其耐受性良好并且存放稳定。所述的新的给药形式是非水或油性的注射制剂，可以通过就地制备相对不稳定的活性成分的游离碱并随后使其稳定制得。本发明的另一方面涉及所述的油性注射制剂及其在治疗生产性牲畜或家畜传染病的方法中的用途。
在本发明中，喔尼妙林应理解为是指下式I所示的化合物喔尼妙林记载于EP-0153277中，并在其中的实施例12中做了具体描述。喔尼妙林的商标名为Econor。
已知该化合物在例如口服或胃肠外给药后具有抗菌特性，可在动物卫生领域用于预防或治疗一系列细菌感染。其广谱活性包括Streptococcusaronson、金黄色葡萄球菌、关节炎枝原体、牛生殖道枝原体、公牛枝原体、牛鼻枝原体、枝原体种、犬枝原体、狸猫枝原体、发酵枝原体、鸡枝原体、鸡败血枝原体、A.granularum、人型枝原体、猪鼻枝原体、Actinobacilluslaidlawii、火鸡枝原体、溶神经枝原体、肺炎枝原体和猪肺炎枝原体。
WO 98/01127记载了其对于在将动物关在非常狭小的空间中(放养密度增加，例如为了运输的目的，在该情况下动物会处于很高的紧张状态)时可能出现的疾病综合征的优良活性。在该情况下起决定作用的最常见的病原体是猪肺炎枝原体、猪痢疾小蛇菌(以前称为猪痢疾密螺旋体)、Serpulinapi1osicoli、Lawsonia intracellularis、鸡败血枝原体、多杀巴斯德氏菌、大叶性肺炎放线杆菌(大叶性肺炎嗜血菌)和副猪嗜血菌，从而呼吸道疾病和其它感染经常一起出现并导致复杂的临床表现。所有的群居动物例如牛、绵羊和猪以及家禽均会感染。
游离形式的喔尼妙林(喔尼妙林碱)相对不稳定，因此主要以其盐、特别是盐酸盐的形式使用。目前在动物卫生领域采用的施用抗生素的方法是注射，因其适于施用控制的单个剂量，从而可以施用针对个体需要而确定的量。这在动物医学领域对于成功地控制多种传染性疾病通常是非常重要。相反，口服给药则不能控制的如此之好，因此在人用药中更为常用。
但是，已经证实大部分家畜、特别是猪对于喔尼妙林盐的含水注射溶液、甚至是油性注射混悬液的耐受性非常差。已经观察到了从轻度皮肤刺激到难以愈合的坏死的损伤。这也是喔尼妙林迄今为止仍主要通过口服应用的原因之一。此外，水溶液通常不能表现出所需的储库作用。另一个问题是喔尼妙林不能以所谓的喔尼妙林碱的游离形式以工业量生产，而是以盐的形式生产，因此一直以盐的形式用于治疗。
但是，对于商业应用，极为需要稳定的、可储存的、油性的并且可耐受的注射制剂。
现已出人意料地发现，可以就地生产喔尼妙林的化学稳定的非水注射制剂并且可以在非水和油性溶剂中稳定。
根据本发明，用于就地生产喔尼妙林游离碱的适宜非水或油性溶剂(i)是肉豆蔻酸异丙酯、甘油或乙二醇或丙二醇与短链至中链的单或二元羧酸的半合成以及合成的酯，例如单、二和三甘油酯(例如中性油或三甘油辛-酸酯)。
为了稳定游离碱，可以向这些溶剂(i)中加入其它的溶剂(ii)，例如中链至长链羧酸(例如乳酸、月桂酸、肉豆蔻酸、棕榈酸、硬脂酸和油酸等)和一元醇(例如乙醇、正丙醇、2-丙醇等)的酯、1，2-O-异丙叉甘油、甘油、乙醇、N，N-二甲基乙酰胺、苯甲酸苄酯或四甘醇，从而在最终产物中存在溶剂(i)和溶剂(ii)的混合物(iii)。加入溶剂(ii)可以改善盖伦特性。特别优选的溶剂(i)是肉豆蔻酸异丙酯并加入溶剂(ii)苯甲酸苄酯或乙醇。
本发明的一个优选实施方案的特点在于溶剂(i)和(ii)在最终产物中的比例约为70∶15。
如上所述，喔尼妙林的游离碱目前还不能大规模地得到。因此，在下文中描述了一种新的和出人意料的就地制备该游离碱并将其配制成稳定形式的方法。
为此，将0.5至30％(重量)、优选5至10％(重量)的喔尼妙林盐悬浮在浓度为50至99％(重量)的非水溶剂(i)中。向悬浮液中加入适宜的碱性赋形剂并在约50至80℃的温度下搅拌和温和地加热，以就地释放喔尼妙林碱，而游离碱立即溶于溶剂(i)中。
用于就地释放喔尼妙林游离碱的适宜碱性赋形剂是，例如碱金属和碱土金属碳酸盐、碳酸氢盐和氢氧化物或有机胺，例如三乙胺。
该过程完成后，将不互溶的两相(水相和非水相)在约50至80℃的温度下相互分离。该相分离可以借助离心来进行。将分离的非水相(现在含有(I)的游离碱)用水在室温下洗涤数次，然后再次在约50至80℃的温度下进行相分离。然后将非水相用例如真空进行干燥，以除去残余的水和挥发性物质例如有机胺，然后将其与第(ii)组的溶剂或溶剂混合物混和以使其稳定。(ii)的加入改善了制剂的盖伦特性。
为了防止氧化的影响，可向所得到的溶液中加入生理可接受的抗氧剂，例如抗坏血酸的酯、丁基羟基甲苯、丁基羟基苯甲醚、没食子酸丙酯、生育酚或生育酚衍生物等，为了防止微生物的感染，可以加入生理可接受的防腐剂，例如苄醇、氯甲酚、氯丁醇、对羟基苯甲酸的酯、苯氧基乙醇、苯酚和苯酚衍生物、山梨酸等。
将最终的溶液无菌过滤或在最终的容器例如安瓿中灭菌。
因此，本发明实质上包括如下优选的方面：
生产非水注射制剂的方法，所述制剂含有喔尼妙林游离碱作为活性成分，选择性地含有稳定剂以防止氧化的影响，还选择性地含有稳定剂以防止微生物感染，该方法的特征在于，在上述类型(i)的生理可接受的非水溶剂或溶剂混合物中从盐的形式就地生产喔尼妙林游离碱并加入选自上述类型(ii)的另一种溶剂进行稳定。
一个优选的实施方案的特征在于，使上述类型(i)的生理可接受的非水溶剂或溶剂混合物中的0.5至30％(重量)的喔尼妙林盐在温和地加热并加入适宜碱性赋形剂的同时就地释放。
优选使用一种或多种溶剂作为上述类型(i)的非水溶剂或溶剂混合物，它们选自肉豆蔻酸异丙酯、半合成和合成的甘油或乙二醇或丙二醇与短链至中链的单或二元羧酸的酯，中链至长链的羧酸与一元醇的酯。
另一个值得注意的实施方案的特征在于，将喔尼妙林的盐悬浮在浓度为50至99％(重量)的溶剂中，用适宜的碱性赋形剂在温和的加热和搅拌下就地生产喔尼妙林的游离碱。
在该方法的另一种优选形式中，为了在物理上稳定喔尼妙林碱，加入中链至长链的羧酸与一元醇的酯、1，2-O-异丙叉甘油、甘油、乙醇、N，N-二甲基乙酰胺、苯甲酸苄酯或四甘醇作为上述类型(ii)的稳定溶剂。
在优选的实施方案中，溶剂(i)和(ii)在最终产物中的比例约为70∶15。
该方法的一个特别优选的方式的特征在于，将喔尼妙林的盐悬浮在溶剂或溶剂混合物(i)中，向悬浮液中加入适宜的碱性赋形剂并在约50至约80℃的温度下进行搅拌和温和地加热以就地释放喔尼妙林碱，所形成的游离碱被该溶剂(i)吸收；该过程结束后，将不互溶的两相(水相和非水相)在约50至约80℃的温度下相互分离；将分离出的非水相(现在含有(I)的游离碱)用水在室温下洗涤数次，然后再次在约50至80℃的温度下进行相分离；然后将非水相干燥并除去挥发性成分，然后将其与第(ii)组的溶剂或溶剂混合物混和以使其稳定。
本发明的另一个目的是含有喔尼妙林游离碱作为活性成分的油性的、稳定的注射制剂，该制剂可以通过以上描述的释放和稳定方法之一制得。本发明还包括所述的油性注射制剂在治疗生产性牲畜或家畜传染病的方法中的用途。
制剂实施例
实施例1：注射制剂
每100mL制得的注射制剂含有5g喔尼妙林碱。在圆括号前给出的克数(制剂1：90.0g，制剂2：85.0g，制剂3：86.0g)是肉豆蔻酸异丙酯、乙醇和苯甲酸苄酯的混合物密度不同的结果。在制剂中给出两个数字的原因是成分以克来称量的，但测出的是体积的量(ml)。
化学稳定性数据喔尼妙林油性注射液的稳定性(％)：
n.a.表示未测定。大于100％的值是由于分析方法的偏差引起的。
| 制剂1 | g |
| 喔尼妙林 | 5.0 |
| 苯甲酸苄酯 | 15.1 |
| 肉豆蔻酸异丙酯 | 69.9 |
| 90.0(100.0mL) |
| 制剂2 | g |
| 喔尼妙林 | 5.0 |
| 乙醇 | 13.5 |
| 肉豆蔻酸异丙酯 | 66.5 |
| 85.0(100.0mL) |
| 制剂3 | g |
| 喔尼妙林 | 5.0 |
| 肉豆蔻酸异丙酯 | 81.0 |
| 86.0(100.0mL) |
| 喔尼妙林的含量 | 25℃/60％相对湿度 | 40℃/75％相对湿度 | ||||
| 制剂1 | 制剂2 | 制剂3 | 制剂1 | 制剂2 | 制剂3 | |
| 0个月后 | 99.2 | 99.8 | 98.5 | 99.2 | 99.8 | 98.5 |
| 1个月后 | 99.9 | 99.2 | 98.9 | 99.7 | 100.4 | 98.4 |
| 2个月后 | 100.2 | 100.5 | 100.3 | 99.4 | 100.4 | 99.4 |
| 3个月后 | 101.2 | 102.0 | 99.6 | 100.2 | 101.2 | 100.8 |
| 6个月后 | 101.4 | 100.4 | n.a. | 98.9 | 99.2 | n.a. |
所有三种制剂均被证实是化学稳定的。喔尼妙林盐酸盐的油性混悬液的稳定性(％)：
大于100％的值是由于分析方法的偏差引起的。耐受性数据
| 喔尼妙林的含量 | 25℃/60％相对湿度 | 40℃/75％相对湿度 |
| 0周后 | 102.0 | 102.0 |
| 8周后 | 104.8 | 102.8 |
通过对猪肌肉内注射注射制剂并评估其对附近组织的影响来进行耐受性的研究。
| 坏死的直径(cm) | ||||
| 制剂1 | 安慰剂 | 制剂2 | 安慰剂 | |
| 颈部区域 | 1 | 0 | 4 | n.a. |
| 大腿 | 1 | n.a. | 3 | 5 |
将制剂与安慰剂进行了比较。结果证实两种制剂并未显示出明显比安慰剂差的耐受性。
Claims (9)
1.生产非水注射制剂的方法，该制剂含有
(a)喔尼妙林游离碱作为活性成分；
(b)选择性地含有一种稳定剂以防止氧化的影响，并且
(c)还选择性地含有一种稳定剂以防止微生物感染；
该方法包括在生理可接受的非水溶剂或溶剂混合物(i)中从盐的形式就地生产喔尼妙林游离碱并通过加入另一种溶剂(ii)使其稳定。
2.权利要求1所述的制备方法，其中，使生理可接受的非水溶剂或溶剂混合物(i)中的0.5至30％(重量)的喔尼妙林盐在温和地加热并加入适宜碱性赋形剂的同时就地释放。
3.权利要求1或2所述的制备方法，其中使用一种或多种溶剂作为非水溶剂或溶剂混合物(i)，这些溶剂选自肉豆蔻酸异丙酯、半合成和合成的甘油或乙二醇或丙二醇与短链至中链的单或二元羧酸的酯，中链至长链的羧酸与一元醇的酯。
4.权利要求1至3中任意一项所述的制备方法，其中，将喔尼妙林的盐悬浮在浓度为50至99％(重量)的溶剂中，用适宜的碱性赋形剂在温和的加热和搅拌下就地生产喔尼妙林的游离碱。
5.权利要求1至5中任意一项所述的制备方法，其中，为了在物理上稳定喔尼妙林碱，加入中链至长链的羧酸与一元醇的酯、1，2-O-异丙叉甘油、甘油、乙醇、N，N-二甲基乙酰胺、苯甲酸苄酯或四甘醇作为稳定溶剂(ii)。
6.权利要求1至5中任意一项所述的制备方法，其中，溶剂(i)和(ii)在最终产物中的比例约为70∶15。
7.权利要求1至5中任意一项所述的制备方法，其中，将喔尼妙林的盐悬浮在溶剂或溶剂混合物(i)中，向悬浮液中加入适宜的碱性赋形剂并在约50至约80℃的温度下进行搅拌和温和地加热以就地释放喔尼妙林碱，所形成的游离碱被该溶剂(i)吸收；该过程结束后，将不互溶的两相，水相和非水相，在约50至约80℃的温度下相互分离；将分离出的含有(I)的游离碱的非水相用水在室温下洗涤数次，然后再次在约50至80℃的温度下进行相分离；然后将非水相干燥并除去挥发性成分，然后将其与第(ii)组的溶剂或溶剂混合物混和以使其稳定。
8.可以按照权利要求1至7中任意一项所述的方法制得的含有喔尼妙林游离碱作为活性成分的油性的、稳定的注射制剂。
9.权利要求8所述的注射制剂在治疗生产性牲畜或家畜传染病的方法中的用途。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99811128.0 | 1999-12-09 | ||
| EP99811128 | 1999-12-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1409631A true CN1409631A (zh) | 2003-04-09 |
| CN1188122C CN1188122C (zh) | 2005-02-09 |
Family
ID=8243176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008168830A Expired - Lifetime CN1188122C (zh) | 1999-12-09 | 2000-12-07 | 新制剂 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6284792B1 (zh) |
| EP (1) | EP1235566B1 (zh) |
| JP (1) | JP3864090B2 (zh) |
| KR (1) | KR100491464B1 (zh) |
| CN (1) | CN1188122C (zh) |
| AR (1) | AR029777A1 (zh) |
| AT (1) | ATE291422T1 (zh) |
| AU (1) | AU769857B2 (zh) |
| BR (1) | BR0016262B1 (zh) |
| CA (1) | CA2390047C (zh) |
| DE (1) | DE60018967T2 (zh) |
| DK (1) | DK1235566T3 (zh) |
| ES (1) | ES2240232T3 (zh) |
| MX (1) | MXPA02005705A (zh) |
| PT (1) | PT1235566E (zh) |
| RU (1) | RU2270676C2 (zh) |
| TW (1) | TWI228048B (zh) |
| WO (1) | WO2001041758A2 (zh) |
| ZA (1) | ZA200204460B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101947203A (zh) * | 2010-10-14 | 2011-01-19 | 郑州后羿制药有限公司 | 一种兽用盐酸沃尼妙林乳剂及其制备方法 |
| CN101744799B (zh) * | 2008-12-12 | 2012-01-11 | 北京大北农科技集团股份有限公司 | 一种兽用沃尼妙林及其盐的脂质体新剂型及其制备方法 |
| CN103288694A (zh) * | 2013-06-28 | 2013-09-11 | 宁夏泰瑞制药股份有限公司 | 一种截短侧耳素类合成衍生物盐的晶体制备方法 |
| CN103520099A (zh) * | 2013-10-30 | 2014-01-22 | 王玉万 | 含有效成份为沃尼妙林的长效注射剂 |
| CN103705454A (zh) * | 2014-01-07 | 2014-04-09 | 王玉万 | 含盐酸沃尼妙林/泊洛沙姆407的油质注射剂 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5390081A1 (es) * | 2001-11-28 | 2004-04-30 | Novartis Ag | Compuestos organicos |
| US6918561B2 (en) * | 2002-10-31 | 2005-07-19 | Yon So Chong | Shell assembly for winding tire cord strip or belt cord strip |
| CN103483232B (zh) * | 2013-09-25 | 2015-05-13 | 宁夏泰瑞制药股份有限公司 | 一种盐酸沃尼妙林的精制方法 |
| CN104689324A (zh) * | 2014-07-30 | 2015-06-10 | 王玉万 | 含亲水性治疗药物可乳化油质注射剂的制备方法 |
| CN104311464A (zh) * | 2014-09-15 | 2015-01-28 | 河北威远动物药业有限公司 | 一种兽用沃尼妙林的制备方法 |
| KR102098289B1 (ko) * | 2018-04-11 | 2020-04-07 | 경북대학교 산학협력단 | 발네물린을 유효성분으로 함유하는 골 질환 예방 또는 치료용 조성물 |
| CN108635333B (zh) * | 2018-07-10 | 2021-10-01 | 四川通达动物保健科技有限公司 | 一种盐酸沃尼妙林冻干粉针剂及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU208115B (en) * | 1989-10-03 | 1993-08-30 | Biochemie Gmbh | New process for producting pleuromutilin derivatives |
| GB9614017D0 (en) * | 1996-07-04 | 1996-09-04 | Biochemie Gmbh | Organic compounds |
-
2000
- 2000-11-07 TW TW089123461A patent/TWI228048B/zh not_active IP Right Cessation
- 2000-12-07 CA CA2390047A patent/CA2390047C/en not_active Expired - Lifetime
- 2000-12-07 DK DK00990671T patent/DK1235566T3/da active
- 2000-12-07 AT AT00990671T patent/ATE291422T1/de active
- 2000-12-07 AU AU30077/01A patent/AU769857B2/en not_active Ceased
- 2000-12-07 MX MXPA02005705A patent/MXPA02005705A/es active IP Right Grant
- 2000-12-07 EP EP00990671A patent/EP1235566B1/en not_active Expired - Lifetime
- 2000-12-07 AR ARP000106515A patent/AR029777A1/es not_active Application Discontinuation
- 2000-12-07 CN CNB008168830A patent/CN1188122C/zh not_active Expired - Lifetime
- 2000-12-07 ES ES00990671T patent/ES2240232T3/es not_active Expired - Lifetime
- 2000-12-07 BR BRPI0016262-0A patent/BR0016262B1/pt active IP Right Grant
- 2000-12-07 DE DE60018967T patent/DE60018967T2/de not_active Expired - Lifetime
- 2000-12-07 WO PCT/EP2000/012346 patent/WO2001041758A2/en active IP Right Grant
- 2000-12-07 PT PT00990671T patent/PT1235566E/pt unknown
- 2000-12-07 RU RU2002118336/15A patent/RU2270676C2/ru active
- 2000-12-07 KR KR10-2002-7007333A patent/KR100491464B1/ko active IP Right Grant
- 2000-12-07 JP JP2001543103A patent/JP3864090B2/ja not_active Expired - Lifetime
- 2000-12-08 US US09/733,477 patent/US6284792B1/en not_active Expired - Lifetime
-
2002
- 2002-06-04 ZA ZA200204460A patent/ZA200204460B/xx unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744799B (zh) * | 2008-12-12 | 2012-01-11 | 北京大北农科技集团股份有限公司 | 一种兽用沃尼妙林及其盐的脂质体新剂型及其制备方法 |
| CN101947203A (zh) * | 2010-10-14 | 2011-01-19 | 郑州后羿制药有限公司 | 一种兽用盐酸沃尼妙林乳剂及其制备方法 |
| CN103288694A (zh) * | 2013-06-28 | 2013-09-11 | 宁夏泰瑞制药股份有限公司 | 一种截短侧耳素类合成衍生物盐的晶体制备方法 |
| CN103288694B (zh) * | 2013-06-28 | 2015-06-17 | 宁夏泰瑞制药股份有限公司 | 一种截短侧耳素类合成衍生物盐的晶体制备方法 |
| CN103520099A (zh) * | 2013-10-30 | 2014-01-22 | 王玉万 | 含有效成份为沃尼妙林的长效注射剂 |
| CN103705454A (zh) * | 2014-01-07 | 2014-04-09 | 王玉万 | 含盐酸沃尼妙林/泊洛沙姆407的油质注射剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60018967T2 (de) | 2006-03-23 |
| JP3864090B2 (ja) | 2006-12-27 |
| US6284792B1 (en) | 2001-09-04 |
| BR0016262B1 (pt) | 2014-10-21 |
| MXPA02005705A (es) | 2002-09-18 |
| WO2001041758A2 (en) | 2001-06-14 |
| US20010021693A1 (en) | 2001-09-13 |
| WO2001041758A3 (en) | 2002-03-07 |
| KR20020064335A (ko) | 2002-08-07 |
| CA2390047C (en) | 2010-03-16 |
| ATE291422T1 (de) | 2005-04-15 |
| AU769857B2 (en) | 2004-02-05 |
| ES2240232T3 (es) | 2005-10-16 |
| EP1235566A2 (en) | 2002-09-04 |
| WO2001041758A8 (en) | 2002-08-29 |
| AU3007701A (en) | 2001-06-18 |
| RU2270676C2 (ru) | 2006-02-27 |
| AR029777A1 (es) | 2003-07-16 |
| DK1235566T3 (da) | 2005-06-20 |
| TWI228048B (en) | 2005-02-21 |
| PT1235566E (pt) | 2005-08-31 |
| CN1188122C (zh) | 2005-02-09 |
| BR0016262A (pt) | 2002-08-13 |
| DE60018967D1 (de) | 2005-04-28 |
| ZA200204460B (en) | 2003-09-03 |
| JP2003516352A (ja) | 2003-05-13 |
| EP1235566B1 (en) | 2005-03-23 |
| KR100491464B1 (ko) | 2005-05-25 |
| CA2390047A1 (en) | 2001-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1188122C (zh) | 新制剂 | |
| EP2063869B1 (en) | Soft chewable veterinary antibiotic formulations | |
| JP4863867B2 (ja) | 制御放出システム | |
| US12005071B2 (en) | Injectable antibiotic formulations and use thereof | |
| JP4584715B2 (ja) | 持続放出性医薬組成物 | |
| CN101972226B (zh) | 一种兽用盐酸多西环素注射液及其制备方法 | |
| CN100348185C (zh) | 含有截短侧耳素衍生物的微球 | |
| US6174866B1 (en) | Edible anti-parasite medication for domesticated animals | |
| EP1190715B1 (en) | Bactericide comprising hinokitiol against vancomycin resistant enterococcus | |
| AU2002319190B2 (en) | Synergistic antibiotic compositions | |
| CN109394688A (zh) | 一种恩诺沙星注射液及其制备方法 | |
| AU2002319190A1 (en) | Synergistic antibiotic compositions | |
| RU2563826C1 (ru) | Инъекционная антибактериальная фармацевтическая композиция | |
| CN113318106B (zh) | 一种兽用长效复方阿莫西林油混悬注射剂及其制备方法 | |
| JP2001131061A (ja) | バンコマイシン耐性腸球菌用殺菌剤 | |
| CN106913517B (zh) | 在胆汁中具有高溶出度的伊维菌素类药物组合物 | |
| KR20120072050A (ko) | 가축의 체중 증가를 위한 α-리포산 함유 사료조성물 및 이의 제조방법 | |
| US4170645A (en) | Antibacterial agent BM123γ, salts and alkyl derivatives thereof for the control of shipping fever in cattle | |
| CN110248643A (zh) | 含普拉沙星的液体组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
| ASS | Succession or assignment of patent right |
Owner name: SWISS NOVARTIS ANIMAL HEALTH CO., LTD. Free format text: FORMER OWNER: NOVARTIS CO., LTD. Effective date: 20150424 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150424 Address after: Basel Patentee after: Animal health company limited of Novartis of Switzerland Address before: Basel Patentee before: Novartis Ag |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Swiss Iran animal health care Co., Ltd. Address before: Basel Patentee before: Animal health company limited of Novartis of Switzerland |
|
| CP01 | Change in the name or title of a patent holder | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050209 |
|
| CX01 | Expiry of patent term |